Janssen Pharmaceutica N.V., Janssen L.P., and Synaptech, Inc. (“Janssen”), appeal from a final judgment of the United States District Court for the District of Delaware. After a bench trial, the district court determined that the claims of U.S. Patent No. 4,663,318 (“the ’318 patent”) were invalid for lack of enablement. In re ’318 Patent Infringement Litig., 578 F. Supp. 2d 711, 737 (D. Del. 2008). We affirm.
Contact Information
- Lisa M. Gehrke, JD, MA
- James B. Gehrke, JD
- Therese M. Pease, JD
- Gehrke & Associates, SC
123 North 86th Street
Wauwatosa, WI 53226
USA
(414) 774-0874
(414) 774-4837 Fax
Follow Us
Categories
- Antitrust
- Bioethics
- Business Law
- Copyright
- Domain Names
- Events
- Firm Updates
- Government Relations
- Licensing
- Music
- Patent
- Patent Case Law
- Patent Case Law -- US Court of Appeals for the Federal Circuit
- Plant Variety Protection
- Right of Publicity
- Technology
- Trade Secrets
- Trademark
- Trademark Case Law
- Trademark Case Law -- US Court of Appeals for the Federal Circuit
- U.S. Supreme Court Decisions
- Useful Information
- USPTO Information
- Web/Tech
Wisconsin Advanced Technology Advocates, Inc.
Creative Protection
Disclaimer
Our web site contains information only and is not intended to create or solicit an attorney-client relationship. Although we welcome your questions and comments, contacting us from this web site does not create an attorney-client relationship. Information you may choose to disclose is not privileged or confidential. Nothing on our web site constitutes "legal advice." If you think you may need legal advice, we urge you to consult a lawyer to discuss your unique circumstances.
© 2002-2011 Gehrke & Associates, S.C.
